EA201270535A1 - Пуриновые производные, применимые в качестве ингибиторов hsp90 - Google Patents

Пуриновые производные, применимые в качестве ингибиторов hsp90

Info

Publication number
EA201270535A1
EA201270535A1 EA201270535A EA201270535A EA201270535A1 EA 201270535 A1 EA201270535 A1 EA 201270535A1 EA 201270535 A EA201270535 A EA 201270535A EA 201270535 A EA201270535 A EA 201270535A EA 201270535 A1 EA201270535 A1 EA 201270535A1
Authority
EA
Eurasian Patent Office
Prior art keywords
purine derivatives
hsp90 inhibitors
derivatives applicable
applicable
formulas
Prior art date
Application number
EA201270535A
Other languages
English (en)
Other versions
EA029272B1 (ru
Inventor
Габрьела Кьосис
Тони Талдоне
Вэйлинь Сунь
Original Assignee
Слоун-Кеттеринг Инститьют Фор Кансер Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Слоун-Кеттеринг Инститьют Фор Кансер Рисерч filed Critical Слоун-Кеттеринг Инститьют Фор Кансер Рисерч
Publication of EA201270535A1 publication Critical patent/EA201270535A1/ru
Publication of EA029272B1 publication Critical patent/EA029272B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Данная заявка обеспечивает замещенные пуриновые производные и родственные соединения показанных формул. Эти соединения пригодны в ингибировании hsp90 и, следовательно, в лечении заболевания. В формулах Z-Z, Х-Х, Х, Х, Y и R являются такими, как определено в описании.
EA201270535A 2009-10-07 2010-10-07 Пуриновые производные, применимые в качестве ингибиторов hsp90 EA029272B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24934909P 2009-10-07 2009-10-07
PCT/US2010/051872 WO2011044394A1 (en) 2009-10-07 2010-10-07 Purine derivatives useful as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
EA201270535A1 true EA201270535A1 (ru) 2012-09-28
EA029272B1 EA029272B1 (ru) 2018-03-30

Family

ID=43857159

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270535A EA029272B1 (ru) 2009-10-07 2010-10-07 Пуриновые производные, применимые в качестве ингибиторов hsp90

Country Status (16)

Country Link
US (2) US9328114B2 (ru)
EP (2) EP3091019B1 (ru)
JP (3) JP5941407B2 (ru)
KR (2) KR101906568B1 (ru)
CN (3) CN102639534A (ru)
AU (1) AU2010303343B2 (ru)
BR (1) BR112012008019A2 (ru)
CA (1) CA2776308C (ru)
DK (1) DK2486039T3 (ru)
EA (1) EA029272B1 (ru)
ES (2) ES2733131T3 (ru)
LT (1) LT2486039T (ru)
MX (1) MX340714B (ru)
NZ (2) NZ599138A (ru)
PT (1) PT2486039T (ru)
WO (1) WO2011044394A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2656202C (en) 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
BR112012008019A2 (pt) 2009-10-07 2016-03-01 Sloan Kettering Inst Cancer derivados de purina úteis como inibidores de hsp90
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
CA2841173C (en) 2011-07-08 2022-06-21 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用
CN111285813A (zh) 2013-08-23 2020-06-16 润新生物公司 化学实体、组合物和方法
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
AU2015317632B2 (en) 2014-09-17 2022-01-13 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
EP4006035B1 (en) * 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
JP2020517732A (ja) * 2017-04-24 2020-06-18 サムス セラピューティクス, インコーポレーテッドSamus Therapeutics, Inc. Ｈｓｐ９０阻害剤の経口製剤及び関連する方法
AU2018290288A1 (en) * 2017-06-23 2020-01-16 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841549D1 (de) 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
JP2005519848A (ja) 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
NL1019258C2 (nl) * 2001-10-30 2003-05-02 Iku Holding Montfoort Bv Bevestigingsconstructie, in het bijzonder voor een buitenspiegel van een motorvoertuig.
US7553979B2 (en) 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
MXPA04008312A (es) 2002-02-28 2004-11-26 Astrazeneca Ab Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos.
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
CN101906106A (zh) 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007014361A2 (en) 2005-07-27 2007-02-01 Qualcomm Incorporated System and method for a forward link only protocol suite
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
WO2007143630A2 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with hsp90 inhibitors
CA2656202C (en) * 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
US20080053862A1 (en) 2006-06-30 2008-03-06 Sanford, L.P. Interlocking Nestable Article Holder
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
AU2008229216B2 (en) * 2007-03-20 2013-03-21 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2009007399A1 (en) * 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
JP2011503206A (ja) * 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
BR112012008019A2 (pt) 2009-10-07 2016-03-01 Sloan Kettering Inst Cancer derivados de purina úteis como inibidores de hsp90
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用

Also Published As

Publication number Publication date
JP5941407B2 (ja) 2016-06-29
JP6326088B2 (ja) 2018-05-16
CN105924443A (zh) 2016-09-07
EP2486039B1 (en) 2016-06-01
EP2486039A4 (en) 2012-08-15
WO2011044394A1 (en) 2011-04-14
MX2012004089A (es) 2012-08-23
CN106083855A (zh) 2016-11-09
JP2016145262A (ja) 2016-08-12
EP3091019B1 (en) 2019-04-03
EA029272B1 (ru) 2018-03-30
ES2733131T3 (es) 2019-11-27
CN106083855B (zh) 2020-04-10
CA2776308C (en) 2020-01-28
US20120208806A1 (en) 2012-08-16
KR20180112117A (ko) 2018-10-11
AU2010303343B2 (en) 2015-11-19
KR102129420B1 (ko) 2020-07-03
MX340714B (es) 2016-07-22
US10172863B2 (en) 2019-01-08
KR101906568B1 (ko) 2018-10-10
BR112012008019A2 (pt) 2016-03-01
KR20120083898A (ko) 2012-07-26
NZ625593A (en) 2016-03-31
JP2013507381A (ja) 2013-03-04
EP2486039A1 (en) 2012-08-15
DK2486039T3 (en) 2016-09-12
CN102639534A (zh) 2012-08-15
JP2018104451A (ja) 2018-07-05
NZ599138A (en) 2014-06-27
LT2486039T (lt) 2016-10-10
EP3091019A3 (en) 2017-01-18
PT2486039T (pt) 2016-09-06
US20160310497A1 (en) 2016-10-27
US9328114B2 (en) 2016-05-03
ES2589403T3 (es) 2016-11-14
JP6804483B2 (ja) 2020-12-23
CA2776308A1 (en) 2011-04-14
EP3091019A2 (en) 2016-11-09
AU2010303343A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
CY1118004T1 (el) Αναστολεις cdk
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
NO20081636L (no) FAP - inhibitorer
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201100447A1 (ru) Органические соединения
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201170832A1 (ru) Пуриновые соединения
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA201270339A1 (ru) Замещенные производные ксантина
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
UA111382C2 (uk) Інгібітори протеїнкінази
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU